Advertisement

Topics

[News] Pazopanib for advanced liposarcoma

02:10 EDT 25 Aug 2017 | The Lancet

Results of a prospective, single-arm, multicentre, phase 2 trial suggest that pazopanib might have activity in patients with unresectable or metastatic liposarcoma, a rare malignancy with poor prognosis. Pazopanib is a multi-targeting tyrosine kinase inhibitor approved as second-line therapy for other types of soft tissue sarcoma.

Original Article: [News] Pazopanib for advanced liposarcoma

NEXT ARTICLE

More From BioPortfolio on "[News] Pazopanib for advanced liposarcoma"

Advertisement
Quick Search
Advertisement
Advertisement